Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 4/20 | 0.55 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296 | 0.80 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL14177211 | 0.76 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL1051435 | 0.76 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL3485393 | 0.76 | DPYD (0.53) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL1890981 | 0.73 | DPYD (0.50) | DPYDATAD2MAPTGAAALDH1A1 | |
| Thymine SCHEMBL14695416 | 0.73 | ATAD2 (0.66) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL2001029 | 0.72 | DPYD (0.53) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL6510854 | 0.72 | DPYD (0.49) | DPYDATAD2MAPTGAAALDH1A1 | |
| Eniluracil SCHEMBL37817 | 0.71 | DPYD (1.00) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL189451 | 0.71 | DPYD (1.00) | DPYDATAD2MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3739785-B2 | — | — | 2006-01-25 | — | — | JP | claimed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | claimed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | claimed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | claimed |
| US-5817781-A | ENZYME INHIBITORS; INCREASED PENETRATION OF CELLS; DEACTIVATEPROTEIN SYNTHESIS, RNA, DNA | GILEAD SCIENCES, INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DPYD 18/4885ATAD2 1447/4885MAPT 2827/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | DPYD 18/4885ATAD2 1447/4885MAPT 2827/4885 |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DPYD 18/4885ATAD2 1447/4885MAPT 2827/4885 |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DPYD 18/4885ATAD2 1447/4885MAPT 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.